Possible Molecular Interactions of Bexarotene - A Retinoid Drug and Alzheimer's Aβ Peptide: A Docking Study

Title:Possible Molecular Interactions of Bexarotene - A Retinoid Drug and Alzheimer's Aβ Peptide: A Docking Study

Volume: 14 Issue: 3

Author(s): Zeenat Mirza and Mohd Amin Beg

Affiliation:

Keywords: Alzheimer's therapeutics, amyloid beta peptide, bexarotene, docking, interactions.

Abstract: Background: Alzheimer’s disease (AD) pathogenesis is primarily hallmarked by the production and accumulation of amyloid beta (Aβ) peptide. Along with the understanding of the neurodegenerative disease progression and its pathophysiological mechanisms, development of anti-Aβ targeted effective therapeutics is essential for AD management. Numerous therapeutic approaches targeting the production, toxicity and removal of Aβ are being attempted worldwide. Prime need is to design inhibitors which can slow down the Aβ aggregation process in a physiological environment. Bexarotene (targretin) is the first of the U.S. Food and Drug Administration approved oral retinoid X receptors (RXR)-selective retinoids, or rexinoids. It is effectively used for the treatment of advanced, refractory cutaneous T cell lymphoma, and also reportedly reduces Aβ levels in AD mouse models. Administration of bexarotene facilitates intracellular Aβ clearance via RXR regulated apolipoprotein E (ApoE) production.

Cite this article as:

Mirza Zeenat and Beg Amin Mohd, Possible Molecular Interactions of Bexarotene - A Retinoid Drug and Alzheimer's Aβ Peptide: A Docking Study, Current Alzheimer Research 2017; 14 (3) . https://dx.doi.org/10.2174/1567205013666161114115344